Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

The market implication is less about "which ETF is better" and more about which factor package investors are paying for: low-cost, liquid, large-cap defensives versus a more idiosyncratic, rate-sensitive pharma basket. In a risk-off tape, the cheaper, more diversified vehicle should attract institutional rebalancing flows because the marginal buyer cares about tracking error and liquidity more than backward-looking performance. That is a tailwind for the mega-cap healthcare complex, especially the names that dominate passive ownership and can absorb flows without much balance-sheet risk.

PJP’s recent strength looks more like a momentum trade on concentrated pharmaceutical winners than a durable edge in the wrapper itself. That makes it fragile over a 1-3 month horizon: if one or two top holdings pause on pricing pressure, patent-cycle noise, or a mild de-rating in high-duration growth names, the relative return can compress quickly. Its heavier small/mid-cap exposure also leaves it more exposed to tighter credit, because smaller healthcare companies depend more on refinancing conditions and M&A optionality than the large-cap global bellwethers.

Contrarian view: the crowd may be overlearning from the last 12 months and ignoring that healthcare leadership often rotates. If rate cuts broaden the market or small-cap healthcare gets a bid, PJP can keep outperforming despite the fee drag. The falsifier for a pro-IXJ stance is persistent relative outperformance by PJP alongside improving breadth in smaller pharma/biotech names; the falsifier for a PJP momentum trade is any renewed lag versus the large-cap defensives over the next reporting cycle.